Skip to main content
Announcements

Sidley Represents RemeGen in Expanded US$356 Million Licensing Agreement With Vor Bio

November 16, 2026

Sidley represented RemeGen Co., Ltd., a China-based biopharmaceutical company, in an amendment to its existing licensing agreement with Vor Bio (Nasdaq: VOR), expanding their strategic partnership to include RC298, a next-generation, long-acting dual BAFF/APRIL inhibitor. The agreement provides for US$56 million in upfront payments and up to US$300 million in additional development milestone payments. Under the expanded agreement, Vor Bio will receive exclusive rights to develop and commercialize RC298 outside Greater China. The collaboration is intended to expand Vor Bio’s autoimmune disease treatment portfolio, with RemeGen leading preclinical and Phase 1 clinical development in China.

The Sidley team was led by Lila Hope and Jiqiang (JQ) Lin (Technology and Life Sciences Transactions) and included Joanna Wu and Yuhan Wu (Technology and Life Sciences Transactions); and Steven M. Przesmicki (Emerging Companies and Venture Capital).